SG11202003081WA - Crystalline forms of 3-substituted 1,2,4-oxadiazole - Google Patents
Crystalline forms of 3-substituted 1,2,4-oxadiazoleInfo
- Publication number
- SG11202003081WA SG11202003081WA SG11202003081WA SG11202003081WA SG11202003081WA SG 11202003081W A SG11202003081W A SG 11202003081WA SG 11202003081W A SG11202003081W A SG 11202003081WA SG 11202003081W A SG11202003081W A SG 11202003081WA SG 11202003081W A SG11202003081W A SG 11202003081WA
- Authority
- SG
- Singapore
- Prior art keywords
- oxadiazole
- substituted
- crystalline forms
- crystalline
- forms
- Prior art date
Links
- -1 3-substituted 1,2,4-oxadiazole Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741036169 | 2017-10-11 | ||
PCT/IB2018/057840 WO2019073399A1 (en) | 2017-10-11 | 2018-10-10 | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003081WA true SG11202003081WA (en) | 2020-05-28 |
Family
ID=64664328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003081WA SG11202003081WA (en) | 2017-10-11 | 2018-10-10 | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
Country Status (13)
Country | Link |
---|---|
US (3) | US11136300B2 (ja) |
EP (1) | EP3694841A1 (ja) |
JP (2) | JP2020536872A (ja) |
KR (1) | KR20200068659A (ja) |
CN (2) | CN111194308A (ja) |
AU (2) | AU2018348350B2 (ja) |
BR (1) | BR112020006669A2 (ja) |
CA (1) | CA3078872A1 (ja) |
EA (1) | EA202090536A1 (ja) |
IL (1) | IL273896A (ja) |
PH (1) | PH12020550125A1 (ja) |
SG (1) | SG11202003081WA (ja) |
WO (1) | WO2019073399A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014316682B2 (en) * | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
HRP20220258T1 (hr) | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
WO2019073399A1 (en) | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
US11497734B2 (en) | 2017-11-03 | 2022-11-15 | Aurigene Discovery Technologies Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3227725A (en) | 1962-04-17 | 1966-01-04 | Union Carbide Corp | Certain 3,5-disubstituted 1,2,4-oxadiazole compounds |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
TW201311B (ja) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
CA2143246C (en) | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
WO1999006023A1 (en) | 1997-07-29 | 1999-02-11 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な(−)−ビュープロピオンの薬学的使用 |
BR0013581A (pt) | 1999-08-23 | 2002-07-02 | Dana Faber Cancer Inst Inc | Pd-1, um receptor para b7-4, e usos para isto |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
EP1383912A4 (en) | 2001-04-02 | 2007-11-28 | Wyeth Corp | PD-1, A RECEPTOR FOR B7-4, AND USES THEREOF |
WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
GB0204159D0 (en) | 2002-02-22 | 2002-04-10 | British Biotech Pharm | Metalloproteinase inhibitors |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
EP2113246B1 (en) | 2003-08-07 | 2016-06-22 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
US20090170907A1 (en) | 2005-06-06 | 2009-07-02 | Smithkline Beecham Corporation | Chemical Compounds |
CA2633042A1 (en) | 2005-12-20 | 2007-07-05 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
CN103554095A (zh) | 2006-02-15 | 2014-02-05 | Abbvie公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
SG185979A1 (en) | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
AU2008272818A1 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming Dr | Methods, composition, targets for combinational cancer treatments |
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
ATE551342T1 (de) | 2008-02-22 | 2012-04-15 | Irm Llc | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer |
WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
EP2349266A4 (en) | 2008-10-30 | 2012-06-06 | Elixir Pharmaceuticals Inc | Sulphonamide-containing compounds and their uses |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
WO2011137587A1 (en) | 2010-05-06 | 2011-11-10 | Hutchison Medipharma Limited | Cytokine inhibitors |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012129564A2 (en) | 2011-03-24 | 2012-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome chymotrypsin-like inhibition using pi-1833 analogs |
WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
WO2013046136A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
JP6461800B2 (ja) | 2012-10-04 | 2019-01-30 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ヒトモノクローナル抗pd−l1抗体および使用方法 |
EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
NZ631762A (en) | 2013-01-09 | 2017-02-24 | Gilead Sciences Inc | 5-membered heteroaryls and their use as antiviral agents |
MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
RS60826B1 (sr) | 2013-07-16 | 2020-10-30 | Hoffmann La Roche | Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora |
EP3041828B1 (en) | 2013-09-06 | 2018-05-23 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
WO2016073470A1 (en) | 2014-11-04 | 2016-05-12 | The University Of Kansas | Lkb1-ampk activators for therapeutic use in polycystic kidney disease |
HRP20220258T1 (hr) | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
MX2017011612A (es) | 2015-03-10 | 2018-03-23 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores. |
CA2979145A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
SG11201903103VA (en) | 2016-10-20 | 2019-05-30 | Aurigene Discovery Tech Ltd | Dual inhibitors of vista and pd-1 pathways |
WO2019061324A1 (en) * | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
WO2019073399A1 (en) | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
US11497734B2 (en) | 2017-11-03 | 2022-11-15 | Aurigene Discovery Technologies Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
-
2018
- 2018-10-10 WO PCT/IB2018/057840 patent/WO2019073399A1/en unknown
- 2018-10-10 BR BR112020006669-9A patent/BR112020006669A2/pt unknown
- 2018-10-10 CA CA3078872A patent/CA3078872A1/en active Pending
- 2018-10-10 JP JP2020519338A patent/JP2020536872A/ja active Pending
- 2018-10-10 US US16/755,439 patent/US11136300B2/en active Active
- 2018-10-10 EA EA202090536A patent/EA202090536A1/ru unknown
- 2018-10-10 AU AU2018348350A patent/AU2018348350B2/en active Active
- 2018-10-10 CN CN201880065488.2A patent/CN111194308A/zh active Pending
- 2018-10-10 EP EP18816221.8A patent/EP3694841A1/en active Pending
- 2018-10-10 KR KR1020207009846A patent/KR20200068659A/ko not_active Application Discontinuation
- 2018-10-10 CN CN202311307332.XA patent/CN117417308A/zh active Pending
- 2018-10-10 SG SG11202003081WA patent/SG11202003081WA/en unknown
-
2020
- 2020-03-24 PH PH12020550125A patent/PH12020550125A1/en unknown
- 2020-04-07 IL IL273896A patent/IL273896A/en unknown
-
2021
- 2021-08-30 US US17/461,512 patent/US11680051B2/en active Active
-
2023
- 2023-05-15 US US18/197,414 patent/US20230278970A1/en active Pending
- 2023-05-24 JP JP2023085453A patent/JP2023109937A/ja active Pending
-
2024
- 2024-04-17 AU AU2024202522A patent/AU2024202522A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11136300B2 (en) | 2021-10-05 |
CN117417308A (zh) | 2024-01-19 |
AU2024202522A1 (en) | 2024-05-09 |
US11680051B2 (en) | 2023-06-20 |
JP2020536872A (ja) | 2020-12-17 |
US20200239422A1 (en) | 2020-07-30 |
EA202090536A1 (ru) | 2020-07-22 |
AU2018348350A1 (en) | 2020-04-02 |
EP3694841A1 (en) | 2020-08-19 |
KR20200068659A (ko) | 2020-06-15 |
AU2018348350B2 (en) | 2024-05-02 |
IL273896A (en) | 2020-05-31 |
US20230278970A1 (en) | 2023-09-07 |
CA3078872A1 (en) | 2019-04-18 |
JP2023109937A (ja) | 2023-08-08 |
CN111194308A (zh) | 2020-05-22 |
PH12020550125A1 (en) | 2021-01-25 |
WO2019073399A1 (en) | 2019-04-18 |
BR112020006669A2 (pt) | 2020-09-24 |
US20220048875A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273730A (en) | crystalline forms | |
HK1243337A1 (zh) | 作為免疫調節劑的3-取代的1,3,4-噁二唑和噻二唑化合物 | |
IL269023A (en) | History of Oxadiazole Kills microorganisms | |
IL251037A0 (en) | Crystal structures of 6-carboxy-2-(5,3-dichlorophenyl)-benzoxazole | |
IL271962A (en) | Preparation of 3-aryl-5-trifluoromethyl-4,2,1-converted oxadiazoles | |
IL273896A (en) | Crystal forms of 3-disubstituted 1, 2, 4-oxadiazole | |
IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
IL276644A (en) | crystalline forms | |
IL271399A (en) | Methods for the preparation of heterocyclic 3,1-benzodioxole compounds | |
PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
IL265445A (en) | crystalline forms | |
HK1256825A1 (zh) | 取代的5,6-二氫-6-苯基苯並[f]異喹啉-2-胺化合物的固體形式 | |
IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
IL269792B (en) | Crystalline forms of (s)–apoxolner | |
EP3579729A4 (en) | PILLOW | |
GB2555866B (en) | A novel crystalline form of epocholeone, a process for its preparation and use the same | |
IL270937A (en) | Crystalline forms of saltalicib | |
IL276108A (en) | Crystalline forms of psoorstam | |
GB201715010D0 (en) | Crystalline forms | |
ZA201902553B (en) | Crystalline forms | |
EP3634400A4 (en) | NEW CRYSTALLINE SHAPES | |
GB201704789D0 (en) | Crystalline compounds | |
AU2017900769A0 (en) | Pillow | |
AU2017900448A0 (en) | Pillow |